OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 79. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
A specific biomarker for insoluble tau	1657
Targeting tumour-associated bacteria	1018
A new path to targeted protein degradation?	789
Neutralizing Zika virus	746
The improving benefit–risk balance of phase I cancer trials	654
Tumour cells get a dendritic cell makeover	652
Glucose-sensitive insulin protects against hypoglycaemia	603
Hypoimmune iPSCs escape immune detection	585
Lipid nanoparticle ferries therapeutic mRNA to the placenta	496
New antibiotic for urinary tract infections nabs FDA approval	484
FDA new drug approvals in Q1 2023	460
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	460
Apolipoprotein L2 inhibitor mitigates fibrosis	456
FDA approves second TTR stabilizer for cardiac amyloidosis	449
Targeting drug-resistant glioblastoma	442
Degrading cell-free DNA to prevent recurrent stroke	415
FDA approves a c-MET-targeted ADC for lung cancer	413
Anti-tau antibody stumbles in phase II Alzheimer trial	402
AI serves up target and inhibitor for lung fibrosis	348
Analysis of a decade of post-authorisation studies for medicines approved by the EMA	336
mRNA vaccines for infectious diseases — advances, challenges and opportunities	317
Target identification and assessment in the era of AI	304
Targeting the Hippo pathway in cancer	275
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	268
2022 FDA approvals	262

Chemical engineering of CRISPR–Cas systems for therapeutic application	241
Small-molecule discovery through DNA-encoded libraries	234
Increasing the potency of T cell therapies	232
Small molecule improves muscle function in myasthenia gravis	227
Pushing both sides of the drug pricing aisle	223
TCR-engineered T cells get personal	221
R&D re-balancing act	215
2025’s FDA approvals by regulatory designations	214
Rewired proteostasis in KRAS inhibitor resistance	207
An allosteric site on cereblon	204
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	198
Mimicking the health benefits of exercise	195
Host-directed antiviral blocks SARS-CoV-2 entry	194
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	192
Combating antimicrobial resistance in malaria, HIV and tuberculosis	181
FDA new drug approvals in Q2 2023	169
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	166
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	165
Roads and detours for CAR T cell therapy in autoimmune diseases	160
A peptide-guided strategy for kinase activation	160
The significance of blockbusters in the pharmaceutical industry	157
The antibody–drug conjugate landscape	155
A renaissance in targeting the PI3K/AKT/mTOR pathway	150
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	147
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	147
Novel drug targets in 2025	143
Inhibiting ASGR1 boosts cholesterol removal	141
Antibody–drug conjugates come of age in oncology	139
Pulsatile FXR agonism	135
Amylin takes another shot at the obesity prize	132
Multi-TACs target solid tumours	128
Reducing IL-2 toxicity	123
Immunology on the brain	123
Agonist antibody lowers blood pressure	117
Antiviral peptide nabs FDA approval for hepatitis delta virus infection	113
Monkeypox mRNA vaccine protects mice and macaques	113
The unglamourous AI wins that are quietly transforming drug discovery and development	110
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	106
Neglected tropical diseases go global	105
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	101
Targeting the ECM in melanoma	98
Redirecting mast cells for antigen-specific cancer immunotherapy	97
Ribosome inhibitor combats bacterial drug resistance	95
Designing G-protein-selective allosteric modulators	95
The European Innovation Network as a hub for medicines innovation in Europe	93
Anti-IL-11 antibody shows anti-ageing properties	92
Targeting claudins in cancer	89
Realizing the potential of agonistic antibody immunotherapy	87
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	86
LRRK2-targeted Parkinson disease drug advances into phase III	86

Frameworks for transformational breakthroughs in RNA-based medicines	85
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	84
Engineered parasite delivers proteins to the brain	83
Engineering a compact genome-editing tool	83
Delivering genome editing tools to primary cells	79